schliessen

Filtern

 

Bibliotheken

HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer

PURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer.PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of wome... Full description

Journal Title: Journal of Clinical Oncology 01/01/2000, Vol.18(2), pp.267-267
Main Author: Stark, Azadeh
Other Authors: Hulka, Barbara S. , Joens, Scott , Novotny, Debra , Thor, Ann D. , Wold, Lester E. , Schell, Michael J. , Melton, L. Joseph , Liu, Edison T. , Conway, Kathleen
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0732-183X ; E-ISSN: 1527-7755 ; DOI: http://dx.doi.org/10.1200/JCO.2000.18.2.267
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: crossref10.1200/JCO.2000.18.2.267
title: HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
format: Article
creator:
  • Stark, Azadeh
  • Hulka, Barbara S.
  • Joens, Scott
  • Novotny, Debra
  • Thor, Ann D.
  • Wold, Lester E.
  • Schell, Michael J.
  • Melton, L. Joseph
  • Liu, Edison T.
  • Conway, Kathleen
subjects:
  • Medicine
  • Pharmacy, Therapeutics, & Pharmacology
ispartof: Journal of Clinical Oncology, 01/01/2000, Vol.18(2), pp.267-267
description: PURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer.PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression.RESULTS: Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio ¿OR = 2.2; 95% confidence interval ¿CI, 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P =.06, Fisher's exact test).CONCLUSION: Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.
language: eng
source:
identifier: ISSN: 0732-183X ; E-ISSN: 1527-7755 ; DOI: http://dx.doi.org/10.1200/JCO.2000.18.2.267
fulltext: fulltext
issn:
  • 0732183X
  • 0732-183X
  • 15277755
  • 1527-7755
url: Link


@attributes
ID619926052
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1200/JCO.2000.18.2.267
sourceidcrossref
recordidTN_crossref10.1200/JCO.2000.18.2.267
sourceformatXML
sourcesystemPC
pqid70866844
display
typearticle
titleHER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
creatorStark, Azadeh ; Hulka, Barbara S. ; Joens, Scott ; Novotny, Debra ; Thor, Ann D. ; Wold, Lester E. ; Schell, Michael J. ; Melton, L. Joseph ; Liu, Edison T. ; Conway, Kathleen
ispartofJournal of Clinical Oncology, 01/01/2000, Vol.18(2), pp.267-267
identifier
languageeng
source
lds4120000101
descriptionPURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer.PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression.RESULTS: Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio ¿OR = 2.2; 95% confidence interval ¿CI, 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P =.06, Fisher's exact test).CONCLUSION: Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.
subjectMedicine ; Pharmacy, Therapeutics, & Pharmacology;
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
thumbnail
0$$TPCamazon_thumb
1$$TPCgoogle_thumb
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutCrossref.html$$EView_CrossRef_copyright_notice
search
creatorcontrib
0Stark, Azadeh
1Hulka, Barbara S.
2Joens, Scott
3Novotny, Debra
4Thor, Ann D.
5Wold, Lester E.
6Schell, Michael J.
7Melton, L. Joseph
8Liu, Edison T.
9Conway, Kathleen
titleHER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
general
0English
110.1200/JCO.2000.18.2.267
2CrossRef
sourceidcrossref
recordidcrossref10.1200/JCO.2000.18.2.267
issn
00732183X
10732-183X
215277755
31527-7755
rsrctypearticle
addtitle
0Journal of Clinical Oncology
1JCO
searchscope
0crossref_rest
1CrossRef
2Crossref
3crossref
scope
0crossref_rest
1CrossRef
2Crossref
3crossref
lsr4020000101
lsr4120000101
lsr4320000101
lsr4520000101
tmp012
tmp022
creationdate2000
startdate20000101
enddate20000101
citationpf 267 pt 267 vol 18 issue 2
lsr30VSR-Enriched:[description, subject, pqid]
sort
titleHER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
authorStark, Azadeh ; Hulka, Barbara S. ; Joens, Scott ; Novotny, Debra ; Thor, Ann D. ; Wold, Lester E. ; Schell, Michael J. ; Melton, L. Joseph ; Liu, Edison T. ; Conway, Kathleen
creationdate20000101
lso0120000101
facets
frbrgroupid1243637220938535598
frbrtype5
newrecords20170411
languageeng
creationdate2000
prefilterarticles
rsrctypearticles
creatorcontrib
0Stark, Azadeh
1Hulka, Barbara S.
2Joens, Scott
3Novotny, Debra
4Thor, Ann D.
5Wold, Lester E.
6Schell, Michael J.
7Melton, L. Joseph
8Liu, Edison T.
9Conway, Kathleen
jtitleJournal of Clinical Oncology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Stark
1Hulka
2Joens
3Novotny
4Thor
5Wold
6Schell
7Melton
8Liu
9Conway
aufirst
0Azadeh
1Barbara S.
2Scott
3Debra
4Ann D.
5Lester E.
6Michael J.
7L. Joseph
8Edison T.
9Kathleen
au
0Stark, Azadeh
1Hulka, Barbara S.
2Joens, Scott
3Novotny, Debra
4Thor, Ann D.
5Wold, Lester E.
6Schell, Michael J.
7Melton, L. Joseph
8Liu, Edison T.
9Conway, Kathleen
atitleHER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
jtitleJournal of Clinical Oncology
stitleJCO
risdate20000101
adddate20000101
volume18
issue2
spage267
epage267
pages267-267
issn0732-183X
eissn1527-7755
formatjournal
genrearticle
ristypeJOUR
doi10.1200/JCO.2000.18.2.267
lad012
citing
0$$t=2$$K3=10.1002/1097-0142(197202)29:2<338::AID-CNCR2820290212>3.0.CO;2-U
1$$t=2$$K3=10.1001/jama.1992.03480070057030
2$$t=2$$K3=10.1056/NEJM198501173120303
3$$t=2$$K3=10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I
4$$t=2$$K3=10.1097/00000478-199103000-00001
5$$t=2$$K3=10.1097/00000478-198906000-00007
6$$t=2$$K3=10.1097/00000478-199212000-00001
7$$t=2$$K3=10.1126/science.3798106
8$$t=2$$K3=10.1056/NEJM198811103191902
9$$t=2$$K3=10.1016/0046-8177(92)90257-4
10$$t=2$$K3=10.1136/jcp.48.8.737
11$$t=2$$K3=10.1001/jama.1992.03480190051030
12$$t=2$$K3=10.1002/path.1711610105
13$$t=2$$K3=10.1056/NEJM199405053301802
14$$t=2$$K3=10.1016/0890-8508(90)90035-X
15$$t=2$$K3=10.1016/S0344-0338(11)80508-X
16$$t=2$$K3=10.1038/bjc.1990.9
17$$t=2$$K3=10.1007/s004280050045
18$$t=2$$K3=10.1038/bjc.1988.239
19$$t=2$$K3=10.1093/jnci/90.17.1262
20$$t=2$$K3=10.1007/BF02915114
21$$t=2$$K3=10.1126/science.2470152
22$$t=2$$K3=10.1073/pnas.92.3.744
23$$t=2$$K3=10.1126/science.278.5342.1481
24$$t=2$$K3=10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y
25$$t=2$$K3=10.1093/jnci/84.16.1279
26$$t=2$$K3=10.1200/JCO.1995.13.9.2293
27$$t=2$$K3=10.1172/JCI118890
28$$t=2$$K3=10.1016/S0046-8177(97)90109-X
date2000-01-01